Prospective Registry Of MammaPrint in Breast Cancer Patients with an Intermediate Recurrence Score (PROMIS)

Protocol: 
AAAJ9701

Prospective Registry Of MammaPrint in Breast Cancer Patients with an Intermediate Recurrence Score (PROMIS)

This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.

Are you Eligible? (Inclusion Criteria)

Inclusion Criteria

Women with histologically proven invasive stage I-II, node negative, hormone receptor positive, Her2 negative breast cancer, who received an Oncotype DX intermediate score (18-30).

Exclusion Criteria

Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy; women with insufficient tissue remaining for Mammaprint FFPE

Specialty Area(s)